References

  1. Atta MG, Fine DM. Editorial comment: tenofovir nephrotoxicity-the disconnect between clinical trials and real-world practice. AIDS Read. 2009; 19:118-119. Google Scholar

  2. Terrier Benjamin, Cacoub Patrice. Virus de l'hépatite B, manifestations extrahépatiques immunologiques et risque de réactivation virale. Revue de Médecine Interne. 2011; 32(10): 622-627. Google Scholar

  3. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002; 40: 1331-1333. PubMed | Google Scholar

  4. European Association for the Study of the Liver (EASL 2017). Clinical practice guideline on the management of Hepatitis B virus infection. Journal of Hepatology. 2017; 67(2):370-398. Google Scholar

  5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter. 2013; 3(Suppl): 1-150.

  6. Faye M, Ka EHF, Lemrabott AT et al. Prévalence de la maladie rénale dans une zone semi-urbaine du Sénégal: résultats d'une enquête transversale à la commune de GUEOUL. Communications affichées/Néphrologie et thérapeutique. 2014;10(5): 391-401. Google Scholar

  7. Amet S, Launay-Vachera V, Polb S et al. Prévalence des anomalies rénales dans l'hépatite B chronique : résultats de l'étude HARPE. Communications affichées / Néphrologie & Thérapeutique. 2012; 8(AE35): 390-413.

  8. Shin JH, Kwon HJ, Jang HR et al. Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine. 2016; 95(1): 1-10. PubMed | Google Scholar

  9. Lord A, Ménard C. La néphrotoxicité médicamenteuse. Le Médecin du Québec. 2002; 7(6):55-59.

  10. Thu AM, Poovorawan K, Kittitrakul C et al. Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. BMC Pharmacology and Toxicology. 2015; 16:1-9. PubMed | Google Scholar

  11. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. 2009; 122(7): 672-678. PubMed | Google Scholar

  12. Brahimi M, Lesperres B. Rein et facteurs de risque. Correspondances en risque CardioVasculaire. 2004; 2(4): 163-165.

  13. Gara N, Zhao X, Collins MT et al. Renal tubular dysfunction during long term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012; 35(11): 1317-1325. Google Scholar

  14. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012; 10(8): 941-946. PubMed | Google Scholar

  15. Basit SA, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Review Of Clinical Pharmacology. 2017; 10(7): 707-716. Google Scholar